Allergy & respiratory

Transform your drug development

Tailored solutions to help improve your probability of success in a competitive market

Female doctor examining patient

Quintiles helped develop or commercialize 95% of the Top 20 best-selling allergy products of 2014

Overcoming the hurdles of allergy and respiratory drug development

Allergy and respiratory are two of the most intensely competitive areas in drug development and biopharmaceutical companies have only increasing pressures to deliver more effective treatments through their clinical development programs.  Meeting these challenges requires a comprehensive solution to help you develop your value story early in drug development to maximize your commercial value downstream.

A reputation built on results

  • Quintiles helped develop or commercialize 95% of the Top 20 best-selling allergy products of 2014
  • Quintiles has provided clinical services for >38 allergy studies involving approximately >13,400 subjects, >2,900 sites in 40 countries since 2009
  • Quintiles helped develop or commercialize 90% of the Top 20 best-selling respiratory products of 2014
  • Quintiles has provided clinical services for >170 respiratory studies involving >84,000 subjects and >16,500 investigator sites in 66 countries since 2009


For both established and development-stage biopharma companies, Quintiles works with you to develop and designed a tailored approach to your allergy and respiratory product development from early clinical development to market.

Leverage the collective expertise of our multi-disciplinary team   +

Integrate the scientific, therapeutic, operational, and commercial components of your programs for improved outcomes.

Quintiles brings together a global team of pulmonologists and respiratory medical advisors, with senior project directors and clinical staff trained and/or certified on guidelines including Global Initiative for Asthma (GINA), Global Initiative for Chronic Obstructive Lung Disease (GOLD), and European Respiratory Society (ERS) and American Thoracic Society (ATS) spirometry guidelines.  Read some our latest thinking on key indications

COPD A global survey conducted to determine frequency of exacerbations in COPD patients (poster)
Asthma A global survey conducted to determine current management of asthma (poster)
IPF Key Considerations for Conducting Clinical Trials in Idiopathic Pulmonary Fibrosis (article)
CF Conducting Cystic Fibrosis Clinical Trials: Methodological, Practical, and Ethical Considerations (poster and article)

Quintiles study and team experience also includes:

Access global scale to access the right sites and patients   +

By leveraging our network of established and experienced sites, Quintiles can provide targeted global site selection for allergy, immunotherapeutic and respiratory studies with access to chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and alpha1-antitrypsin deficiency (A1AD).
  • Global reach spans northern and southern hemispheres for sustained recruitment momentum from proof of concept (PoC) into later phase studies
  • Global landscape surveys for indications including asthma, COPD, CF, A1AD covering diagnosis, treatment, standard of care, prevalence of disease
  • Allergy chamber available for environmental allergy studies
Incorporate translational medicine and biomarker integration strategies   +

Identifying robust biomarkers which can serve as a surrogate endpoints that are acceptable to regulators can be challenging.
Quintiles biomarker services, supported by laboratory services through Q2 Solutions, can help you to select and find the right patient populations for your studies by integrating biomarkers into your selection criteria during Phase I and into later phase studies.

  • Expertise in drug delivery for PK/PD bioequivalence, and generic/biosimilar studies 
  • Acute knowledge of first-in-man (FIM) and first-in-patient (FIP) studies
  • Collaborative links to King’s College, Imperial College and University College London
  • Global centralized sputum and airway sample laboratory at Quintiles Phase I unit in London (QLON) (read our latest blog)
  • Challenge studies, bronchoscopy studies, cardiopulmonary exercise test (CPET)
  • Vast experience in spirometry, imaging, data capture methods
Tailored solutions to meet your budget and timeline   +

Setting the course for clinical program success takes up-front planning—learn more about our suite of services designed to help our customers map the best path forward.
Allergy and Respiratory Services   +

Ready to advance your respiratory and allergy studies globally?
  • Dedicated Center for Respiratory & Biomarker Research
  • Proven access to COPD, Asthma, and IPF patient networks
  • Inhaled challenge models including allergy, LPS, and exercise
  • Global Centralized sputum and airway sample laboratory
  • Integrated tissue handling and biomarker identification
  • Targeted global site selection for allergy immunotherapeutic studies
  • Expertise in drug delivery for PK/PD bioequivalence device studies

The power of possibilities

Deploy disruptive innovation to transform allergy and respiratory drug development.

Video Spotlights
Getting more value from Respiratory Clinical Trials
Getting more value from Respiratory Clinical Trials